In the Brief Report titled “Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma,”1 published online March 25, 2021, a grant from the New York University’s Specialized Program of Research Excellence in Melanoma was omitted from the Funding/Support section. This article has been corrected online.
1.Patrinely
JR
Jr, Johnson
R, Lawless
AR,
et al. Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma.
JAMA Oncol. Published online March 25, 2021. doi:
10.1001/jamaoncol.2021.0051PubMedGoogle Scholar